Ką reiškia "Išvalyti"?
Gyvūnas mutacijos nenešioja. Dėl to liga neišsivystys ir neperduos.
Šuo Kerio mėlynojo terjero šunų kelių sistemų degeneracija (CMSD-KBT)
The Canine Multiple System Degeneration (CMSD) DNA test is essential for Kerry Blue Terrier owners to ensure their dogs' health. CMSD is a hereditary neurological disorder affecting coordination and movement in Kerry Blue Terriers. Early genetic testing helps identify carriers and affected dogs, enabling responsible breeding decisions. By using the CMSD DNA test, breeders can reduce the risk of passing this debilitating condition to future generations. This test provides accurate, reliable results, promoting the well-being of your Kerry Blue Terrier. Protect your dog’s health with the CMSD DNA test today. Regular screening supports a healthier, happier canine companion.
Santrumpa: CMSD-KBT
Analizuojama mutacija: SERAC1 c.1536G>A
Paveldėjimas: Autosominis recesyvinis
Akronimas
CMSD-KBT
Stebimas dažnis
Klinikinis sunkumas
Klinikinė klasifikacija
Neurologinės ligos
Analizuojama mutacija
SERAC1 c.1536G>A
p.(Trp512*)
p.(Trp512*)
Paveldėjimo būdas
Autosominis recesyvinis
Bandymo santrauka:
Canine Multiple System Degeneration (CMSD) is a genetic disorder affecting Kerry Blue Terriers, causing progressive neurological decline. A DNA test is available to identify carriers and affected dogs, helping breeders make informed decisions. Early detection through testing can prevent the spread of this debilitating condition within the breed. Responsible breeding practices rely on these genetic insights to maintain healthy Kerry Blue Terrier populations. Overall, the CMSD DNA test is a valuable tool for canine health management.
Galima įsigyti iš pakuotės: Basic
Šis DNR testas įtrauktas nuo mūsų pakuotės Basic — ir taip pat yra pakuotės dalis Basic, Standard, Advanced, Complete.
Peržiūrėkite DNR testų paketus →Pasirinkite pakuotę, kuri geriausiai atitinka jūsų gyvūnų veisimo ar sveikatos strategiją.
Understanding Canine Multiple System Degeneration in Kerry Blue Terriers (CMSD-KBT)
Canine Multiple System Degeneration (CMSD) is a progressive neurological disorder that primarily affects Kerry Blue Terriers. This condition is characterized by the degeneration of multiple systems within the nervous system, leading to a range of debilitating symptoms that can significantly impact the quality of life of affected dogs.
Symptoms of CMSD-KBT
The symptoms of CMSD-KBT typically manifest in early to mid-adulthood, although the age of onset can vary. Common signs include balance problems, difficulty walking, and a general lack of coordination. As the disease progresses, affected dogs may exhibit muscle weakness, tremors, and a decline in overall mobility. In some cases, dogs may also experience changes in behavior, such as increased anxiety or a reluctance to engage in normal activities.
Pathophysiology of CMSD-KBT
The underlying cause of CMSD-KBT lies in genetic mutations that affect the nervous system's ability to function properly. These mutations lead to the degeneration of nerve cells, which in turn causes a breakdown of communication between the brain and the body. This disruption results in the clinical symptoms observed in affected dogs. Understanding the genetic basis of CMSD-KBT is crucial for breeders and owners, as it allows for informed decisions regarding breeding practices and the management of affected animals.
Sergamų šunų valdymas ir priežiūra
While there is currently no cure for CMSD-KBT, management strategies can help improve the quality of life for affected dogs. Regular veterinary check-ups are essential for monitoring the progression of the disease and addressing any health concerns that arise. Physical therapy and rehabilitation exercises can assist in maintaining mobility and strength. Additionally, providing a safe and supportive environment can help dogs cope with their symptoms and enhance their overall well-being.
Išvada
Canine Multiple System Degeneration in Kerry Blue Terriers is a serious condition that requires attention from dog owners and breeders. By understanding the symptoms, underlying causes, and management strategies associated with CMSD-KBT, stakeholders can work towards improving the lives of affected dogs while making informed breeding decisions to reduce the prevalence of this condition in the breed.
Testui pripažinta veislė: Kerio mėlynojo terjero šunų kelių sistemų degeneracija (CMSD-KBT)
- Kerry Blue Terrier
🧬 Interpretation of genotypes CMSD-KBT
Genotipas
Būsena
🟡 N/N
Ne vežėjas – jokios rizikos
🟡 N/CMSD-KBT
Vežėjas – jokios rizikos
❌ CMSD-KBT/CMSD-KBT
Paveikta – rizikuojama
DUK: aiškinimo supratimas
Ar „vežėjas“ rimtas?
Ne. Gyvūnas paprastai yra sveikas, bet gali perduoti savo mutaciją palikuonių.
Ką daryti, jei gyvūnas yra „paveiktas“?
Jame yra dvi mutavusios kopijos. Klinikinių požymių tikimasi priklausomai nuo liga. Jis neturėtų būti veisiamas.
Kodėl yra skirtumų tarp vyrų / moterų?
Kai kurios ligos yra susijusios su lytimi, todėl jų išraiška skiriasi priklausomai nuo gyvūno lytis.
Numatykite palikuonis
N/N (ne-vezejas)
N/CMSD-KBT (Vežėjas)
CMSD-KBT/CMSD-KBT (Paveiktas)
DUK apie DNR testą
Ką nustato šis DNR tyrimas?
This DNA test detects the mutation associated with Canine Multiple System Degeneration In Kerry Blue Terrier (CMSD-KBT) in order to identify clear, carrier, or at-risk animals.
Kodėl verta išbandyti veislinį gyvūną?
DNR tyrimai padeda veisėjams planuoti saugesnį poravimąsi ir sumažinti riziką, kad mutacija bus perduota palikuonims.
Koks yra šio testo paveldėjimo būdas?
Šio testo paveldėjimo režimas yra autosominis recesyvinis.
Kuri mutacija analizuojama atliekant šį testą?
This test analyses the mutation SERAC1 c.1536G>A.
Ar būtinai nukentėjo nešiotojas?
Nebūtinai. Aiškinimas priklauso nuo paveldėjimo modelio ir gauto genotipo.
Nuorodos
Johnson GS, Mhlanga-Mutangadura T, Morava E, Kozicz T, Taylor JF, O’Brien DP, Schnabel RD. Canine Multiple System Degeneration is Associated with Distinct SERAC1 Mutations in Two Different Dog Breeds [abstract]. Presented at the 63rd Annual Meeting of the American Society of Human Genetics in Boston, Massachusetts; 2013 Oct 22-26.